Having focused largely on the drug component of drug-eluting stents, most companies developing the next wave of bioabsorbable stents are working with the same biopolymers. Theracardia, however, begins life with a portfolio of novel biopolymers that inherently have the potential to avoid inflammation in the body, are bioabsorbable and can be engineered to achieve specific biological effects. The company is validating its platform in a stent biocoating in preparation for developing its own improved bioabsorbable stent, one that, it hopes, will promote rapid endothelialization and reduce restenosis without incorporating a drug.
6520 Edenvale Boulevard
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Already a frontrunner in developing the KRAS G12D inhibitor class, analysts think Revolution Medicines could seal its leadership by combining zoldonrasib with other agents in its portfolio.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.
